Home › Funds › Avoro Capital Advisors LLC › ARWR
Avoro Capital Advisors LLC position in ARWR
ARROWHEAD PHARMACEUTICALS IN · Health Care
Avoro Capital Advisors LLC reported holding 11,000,000 shares of ARWR (ARROWHEAD PHARMACEUTICALS IN) in its Q3 2026 13F filing — a position valued at US$720.0M, representing 7.45% of its reported portfolio and ranking #7 among its reported holdings. Avoro Capital Advisors LLC has disclosed ARWR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Avoro Capital Advisors LLC's ARWR position evolved
Avoro Capital Advisors LLC first disclosed a stake in ARWR in Q3 2023 at 565,000 shares (US$15.2M). The position peaked in Q2 2026 at 11,355,555 shares, worth US$925.6M. Across 13 filings, Avoro Capital Advisors LLC increased the stake 7 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 11,000,000 shares valued at US$720.0M — a reduction of -355,555 shares quarter over quarter.. Notable position changes include a 100% increase in Q4 2023 (shares fell 7% over the following quarter), a 657% increase in Q1 2024 (shares fell 9% over the following quarter), a 25% increase in Q4 2024 (shares fell 32% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 565.00K | $15.18M | New |
| Q4 2023 | 1.13M | $34.58M | Add |
| Q1 2024 | 8.56M | $244.69M | Add |
| Q2 2024 | 8.89M | $231.02M | Add |
| Q3 2024 | 8.89M | $172.18M | Hold |
| Q4 2024 | 11.11M | $208.89M | Add |
| Q1 2025 | 11.11M | $141.56M | Hold |
| Q2 2025 | 10.60M | $167.48M | Reduce |
| Q3 2025 | 10.90M | $375.94M | Add |
| Q4 2025 | 10.62M | $705.39M | Reduce |
| Q1 2026 | 10.70M | $670.89M | Add |
| Q2 2026 | 11.36M | $925.59M | Add |
| Q3 2026 | 11.00M | $719.95M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARWR and 13F data
ARWR (ARROWHEAD PHARMACEUTICALS IN) is a Health Care company. 42 other funds we track also report a position in ARWR — the largest reported positions include FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M), Siren, L.L.C. (US$149.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARWR
- FRED ALGER MANAGEMENT, LLC 3.30M sh · $269.14M · Q2 2026
- BAKER BROS. ADVISORS LP 1.99M sh · $162.43M · Q2 2026
- Siren, L.L.C. 2.29M sh · $149.91M · Q3 2026
- Vestal Point Capital, LP 1.57M sh · $128.38M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.39M sh · $113.22M · Q2 2026
- Western Financial Corp/CA 820.24K sh · $53.68M · Q3 2026
- READYSTATE ASSET MANAGEMENT LP 25.00M sh · $29.94M · Q2 2026
- MACKAY SHIELDS LLC 27.19M sh · $27.84M · Q3 2026
- Affinity Asset Advisors, LLC 425.00K sh · $27.82M · Q3 2026
More on Avoro Capital Advisors LLC
FAQ
How long has Avoro Capital Advisors LLC held ARWR?
Avoro Capital Advisors LLC has disclosed ARWR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Avoro Capital Advisors LLC's current position in ARWR?
As of Q3 2026, Avoro Capital Advisors LLC holds 11.00M shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $719.95M, representing 7.45% of its reported portfolio and ranking #7.
Has Avoro Capital Advisors LLC been buying or selling ARWR?
In the latest 13F filing (Q3 2026), Avoro Capital Advisors LLC reduced its position in ARWR. The position peaked in Q2 2026 at 11.36M shares.
Which other funds hold ARWR?
Other major institutional holders of ARWR include FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, Siren, L.L.C., among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.